<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Fifty-six patients older than 65 (median age: 77, range: 65-91) were treated in our general hospital, between January 1991 and November 1995 with the diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Twenty-five were de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (45%) </plain></SENT>
<SENT sid="2" pm="."><plain>The other cases which were considered as <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> (sAML) occurred after: <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (19 cases: 34%), <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> (7: 13%) or therapy of <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> (5: 9%) </plain></SENT>
<SENT sid="3" pm="."><plain>Distribution of FAB subtypes was: M0: 4, M1: 8, M2: 14, M4: 10, M4eo: 1, M5: 10, M6: 1, unclassified: 8 </plain></SENT>
<SENT sid="4" pm="."><plain>Twenty-seven patients (48%) (de novo: 18, sAML: 9) received conventional "3 + 5" or "3 +7" induction chemotherapy +/- consolidation and maintenance (group 1) </plain></SENT>
<SENT sid="5" pm="."><plain>Low-dose Ara-C was given in eighteen cases (32%) (group 2), miscellaneous single agents were prescribed in seven cases and two patients received only supportive care </plain></SENT>
<SENT sid="6" pm="."><plain>Sixteen early <z:hpo ids='HP_0011420'>deaths</z:hpo> (ED) (&lt;1 month) occurred (29%) </plain></SENT>
<SENT sid="7" pm="."><plain>Distribution of age, WHO-PS, hyperleukocytosis, ED and median survival (MS) (3 months) was equivalent in de novo and sAML </plain></SENT>
<SENT sid="8" pm="."><plain>Fifteen CR were achieved including twelve patients from group 1 (no difference between age &lt;75 versus &gt;75 years) and three from group 2 </plain></SENT>
<SENT sid="9" pm="."><plain>The MS of CR patients was 13 months </plain></SENT>
<SENT sid="10" pm="."><plain>Eleven patients survived more than one year (de novo: 8) </plain></SENT>
<SENT sid="11" pm="."><plain>M5 subtype, <z:hpo ids='HP_0001945'>fever</z:hpo> &gt;38 degrees C, high LDH level, WHO-PS&gt;2, CR non achievement were predictive of reduced survival </plain></SENT>
<SENT sid="12" pm="."><plain>Besides conventional induction, investigational therapies currently remain the best antileukemic modalities </plain></SENT>
<SENT sid="13" pm="."><plain>Age per se should not be an exclusion criteria for treatment </plain></SENT>
<SENT sid="14" pm="."><plain>Our data underline the high frequency of sAML in the community </plain></SENT>
<SENT sid="15" pm="."><plain>Of note, this common type <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> is largely excluded from many trials </plain></SENT>
</text></document>